Some drugs used to control high blood pressure and prevent heart failure were voluntarily recalled this past week due to an impurity that could possibly lead to cancer, the U.S. Food and Drug Administration said.
These products — with the active ingredient valsartan, a generic drug used to treat high blood pressure — may contain N-nitrosodimethylamine (NDMA), a possible human carcinogen. The FDA asked three companies, Major Pharmaceuticals, Solco Healthcare and Teva Pharmaceuticals Industries Ltd., to recall their valsartan products. Solco and Teva were also asked to recall their drugs containing valsartan/hydrochlorothiazide (HCTZ).
Researchers led by King’s College London’s Graham Lord conducted a genome-wide association study of organ donor and recipient DNA from about 8,000 pairs of donors and recipients. As they reported in the American Journal of Transplantation this week, they replicated known links between the HLA region and outcomes, but were unable to find any genetic link to outcomes outside that region.
“[W]e identified that this area of DNA alone can tell us whether the match between a kidney donor and recipient will work in the long term,” Lord said in a statement. “This has the potential to improve outcomes for transplant patients and deliver treatments that are more personalized to the health needs of individual patients.”